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To the Editor:
In a recent article by Tsujino 
et al.1 pooled the data from the litera-
ture investigating the effectiveness of 
consolidation chemotherapy (CHT) 
after concurrent radiochemotherapy 
(RT-CHT) in locally advanced non–
small-cell lung cancer (NSCLC). 
They found no difference (survivals, 
toxicity) between RT-CHT followed 
by consolidation CHT and exclusive 
RT-CHT, adding to previous observa-
tions that concurrent RT-CHT is the 
standard treatment in locally advanced 
NSCLC.2–4 Another recent data5 showed 
that concurrent RT-CHT can also be 
considered as one of standards in clini-
cal stage IIIA NSCLC patients.
Although reasons for ineffi-
ciency of consolidation CHT may be 
multiple, it is challenging to disclose 
some aspects that may have adversely 
influenced the outcome. Although these 
studies presented very detailed pat-
tern of failure in general, this was done 
for the whole time period of the study 
(treatment plus follow-up). This way 
we only learned about the total patterns 
of failure and not about which type of 
failure was observed when, that is, after 
concurrent or after consolidation part, 
and particularly in which patients.
Why exact pattern of failure is so 
important? First, there are several types 
of patients after the initial (concurrent) 
part of RT-CHT and they can easily 
be separated regarding the response. 
Although it is extremely unlikely that 
those achieving a stable disease would 
benefit from the consolidation CHT, 
those with either a complete response 
(CR) or a partial response (PR) seem 
as likely candidates (although not all of 
them) to benefit from the consolidation 
CHT. Therefore, separation of pattern of 
failure occurring in likely (CR and PR) 
and unlikely (stable disease) candidates 
could be used for further studies using 
similar design with respect to, for exam-
ple, eligibility criteria. Second, and more 
importantly, among likely candidates 
(CR and PR) to benefit from consolida-
tion CHT, a distinction should be made 
between those achieving CR and those 
achieving PR after concurrent RT-CHT. 
This is so because different mechanisms 
(precisely, different location) of action of 
consolidation CHT would be expected. 
In the CR patients, consolidation CHT 
would target only a microscopic disease 
both intrathoracically and extrathoraci-
cally, whereas in the PR patients, it would 
have also to address clinically overt 
intrathoracic disease. Pattern of failure 
in these two distinct groups of patients 
would then clearly show how and where 
consolidation CHT actually acts and to 
what extent (clinical versus subclinical). 
In addition, we would be able to investi-
gate the determinants of treatment out-
come such as cross-resistance between 
drugs or drugs and RT.
Although identifying pattern of 
failure in patients achieving differ-
ent response after concurrent RT-CHT 
would place additional burden on inves-
tigators and hospitals, this effort would 
be eventually rewarding. This way 
we would be able to identify different 
patient subsets and different options 
and to proceed (or not) with a consoli-
dation CHT, an approach which would 
ultimately lead to a better patient-tai-
lored treatment sequence, a must for a 
future clinical research in lung cancer. 
Branislav Jeremic, MD, PhD
Division of Clinical and 
Radiation Oncology
Stellenbosch University and 
Tygerberg Hospital
Cape Town, South Africa
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In Response:
We thank Dr. Jermic for giv-
ing us an opportunity to express our 
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views in our study. Our pooled anal-
ysis failed to show the efficacy of 
consolidation chemotherapy (CCT) 
in terms of survival prolongation for 
patients with locally advanced non–
small-cell cancer (LA-NSCLC). This 
negative result should carefully be 
assessed because, as Dr. Jermic sug-
gested, our study has several limita-
tions which might affect our study 
result.1 In particular, as our study was 
performed on a publication basis, we 
could not assess the heterogeneity 
at the individual patient level. It is 
important to identify the characteris-
tics of patients who could benefit from 
CCT. However, we could not carry out 
subgroup analyses based on the pat-
terns of treatment failure or responses 
to initial chemo-radiotherapies as our 
analysis did not use individual data of 
each trial.
Another important factor that 
may affect our study result is the 
diversity of CCT regimens among 
trials. We evaluated the effective-
ness of CCT by dividing it into two 
patterns: continuous CCT, which 
continues chemotherapy with agents 
given in the induction therapy, and 
switch CCT (SCCT), which switches 
chemotherapy to different agent(s) in 
the consolidation phase. SCCT might 
be more promising than continuous 
CCT because it is expected to effec-
tively eradicate tumor cells resistant 
to the induction chemo-radiotherapy. 
Although our analyses failed to show 
the efficacy of SCCT, it was prob-
ably because of the small number of 
trials: only four trials were designed 
for SCCT. Further clinical trials on 
SCCT will be warranted to answer 
these queries.
Finally, our pooled analysis 
failed to provide evidence that CCT 
yields significant survival benefit for 
LA-NSCLC patients. However, we 
believe that the findings of this study 
are relevant because it reminds us that 
there is currently no sufficient evi-
dence to support CCT for LA-NSCLC 
patients, and that current recommended 
treatment for LA-NSCLC patients 
remains concurrent chemo-radiother-
apy. Little progress in treatment strate-
gies for LA-NSCLC patients has been 
observed in the last 20 years,2 and it is 
urgent to seek new treatment options/
strategies to improve this. Further stud-
ies, for example, individual patient-
based meta-analyses or prospective 
studies focusing on patterns of treat-
ment failure or responses to initial 
chemo-radiotherapy are needed to 
establish how to use CCT appropriately 
to improve survival of LA-NSCLC 
patients.
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To the Editor:
We congratulate Huang et al.1 for 
their elegant description on how lung 
adenocarcinoma cells may metastasize to 
the ipsilateral parietal pleura, invade the 
chest wall lymphatic vessels which drain 
to the ipsilateral axillary lymph nodes, 
retrogradely spread to the intramammary 
lymphatics, and finally establish ipsi-
lateral breast metastasis. It is plausible 
that the presence of the clinical triad of 
ipsilateral pleural effusion or thickness, 
enlarged ipsilateral axillary lymph nodes 
that are palpable or evident on computed 
tomography (CT), and ipsilateral breast 
metastasis provides support for this pro-
posed mechanism for ipsilateral breast 
metastasis from lung cancer. In addition, 
the presence of intact fat planes between 
the chest wall and breast tissue on CT 
scan excludes direct tumor invasion of the 
breast from the ipsilateral parietal pleural 
metastasis as a less likely mechanism.1
We also like to add that the 
absence of enlarged mediastinal (N2 
or N3 disease) and ipsilateral supracla-
vicular (N3 disease) lymph nodes on 
CT scan and the latter also on palpa-
tion is needed to discount the other pos-
sible mechanism of lymphatic spread 
to ipsilateral axillary lymph nodes 
from mediastinal lymph nodes, through 
intercostal lymphatics2 or retrogradely 
through supraclavicular nodes.3
Whatever the mechanism of 
spread to the axillary lymph nodes, breast 
metastasis is an infrequent manifestation 
of advanced disseminated lung cancer 
and is associated with an extremely poor 
prognosis and a short survival.4,5
As Huang et al.1 has stated, differ-
entiating primary from metastatic breast 
carcinoma is of great clinical importance 
